TD Cowen analyst Ritu Baral maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target ...

Stay up-to-date on the latest stock analyst ratings, including expert upgrades and downgrades, to help you make well-informed investment decisions. Access detailed analyses and recommendations to ...

Stay up-to-date on the latest stock analyst ratings, including expert upgrades and downgrades, to help you make well-informed investment decisions. Access detailed analyses and recommendations to ...

We'll go to the next question. Your next question is from the line of Ritu Baral with TD Cowen. Thanks, Ritu. So no. To be clear, with the six-week data, we are not going to be getting any ...

On Wednesday, TD Cowen maintained a positive stance on Madrigal Pharmaceuticals (NASDAQ:MDGL) shares, with analyst Ritu Baral reiterating a Buy rating and a $390.00 price target. The affirmation ...

Ritu Baral, TD Cowen: Questioned the impact of Medicare's new catastrophic coverage rules. Management explained adjustments to gross-to-net projections, emphasizing a strategic focus on seamless ...

Ritu Baral, TD Cowen: Inquired about pricing and patient access in Europe. Krish Krishnan explained that Germany launches with the U.S. price for six months, followed by pricing negotiations ...